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Efficacy and Safety of Eluxadoline in Patients With
Irritable Bowel Syndrome With Diarrhea Who Report
Inadequate Symptom Control With Loperamide:
RELIEF Phase 4 Study
Darren M. Brenner, MD1, Gregory S. Sayuk, MD2,3, Catherine R. Gutman, PhD4, Esther Jo, MPH5, Steven J. R. Elmes, PhD4,
Louis W. C. Liu, MD, PhD6 and Brooks D. Cash, MD7
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with
limited effective treatment options. We evaluated the efficacy and safety of eluxadoline in
patients with IBS-D who reported inadequate symptom control with prior loperamide.
METHODS: Three hundred forty-six adults with IBS-D (Rome III criteria) were randomly assigned to placebo or
eluxadoline 100mg twice daily for 12 weeks. Patients recorded daily IBS-D symptoms, including worst
abdominal pain (WAP) and stool consistency (through Bristol Stool Scale). The primary endpoint was
proportion of composite responders, defined as patients who met daily composite response criteria
(‡40% WAP improvement and <5 Bristol Stool Scale score) for at least 50% of treatment days, and
recorded ‡60 days of diary entries over the 12-week period.
RESULTS: Over 12 weeks, a significantly greater proportion of eluxadoline patients achieved the primary
composite responder endpoint compared to placebo (22.7% vs 10.3%, P5 0.002), and component
endpoints of improvements in stool consistency (27.9% vs 16.7%, P 5 0.01) and WAP (43.6% vs
31.0%, P5 0.02). Additionally, a greater proportion of eluxadoline patients met the composite
responder endpoint assessed at monthly intervals compared to placebo (weeks 1–4: 14.0% vs 6.9%,
P50.03; weeks 5–8: 26.7%vs 14.9%,P50.006; weeks 9–12: 30.8% vs 16.7%,P50.002). Rates
of adverse events were comparable in both groups (37.4% vs 35.3%); no treatment-related serious
adverse event, cases of sphincter of Oddi spasm, or pancreatitis were reported.
DISCUSSION: Eluxadoline appears safe and effective for treating IBS-D symptoms in patients with an intact
gallbladder reporting inadequate relief with prior loperamide use.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/B246, http://links.lww.com/AJG/B265, http://links.lww.com/AJG/B266, and
http://links.lww.com/AJG/B267
Am J Gastroenterol 2019;114:1502–1511. https://doi.org/10.14309/ajg.0000000000000327
INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional gastro-
intestinal (GI) disorder, with an estimated global prevalence of
11% (1,2). IBS is characterized by regular abdominal pain asso-
ciated with changes in stool frequency and/or consistency and is
subtyped based on the predominant stool pattern: IBS with
constipation, diarrhea (IBS-D), mixed, or unsubtyped. Of the
subtypes, IBS-D is the most common, comprising nearly 45% of
all IBS cases (3).
Effective treatment options for IBS-D are limited, and patients
often resort to interventions based on relieving individual
symptoms. Typical initial therapeutic interventions include di-
etary and lifestyle modifications, as well as over-the-counter
antidiarrheals. Loperamide, a peripherally restricted m-opioid
receptor (m-OR) agonist that mechanistically decreases gut mo-
tility and increases fluid reabsorption, is one of the most com-
monly used agents for themanagement of IBS-D (4,5) despite the
recent American College of Gastroenterology IBS Monograph
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strongly recommending against it as an IBS therapy (6). Loper-
amide is not indicated for long-term use and does not alleviate
abdominal pain or bloating (7–11). Therefore, there is consid-
erable need for new and effective treatments with favorable safety
profiles that hold the potential to provide sustained symptom
relief for patients with IBS-D.
Eluxadoline is a locally acting, mixedm-OR agonist, k-opioid
receptor agonist, and d-opioid receptor (d-OR) antagonist with
minimal oral bioavailability approved by the US Food and Drug
Administration (FDA) for the treatment of IBS-D (12). Owing
to its combined pharmacological profile, eluxadoline reduces
gut motility consistent with its primary role as a m-OR agonist
and, due to its d-OR antagonism, decreases the potential for
medication-induced constipation. Importantly, eluxadolinewas
also shown to improve abdominal pain in 2 randomized, mul-
ticenter, multinational, double-blind, placebo-controlled phase
3 studies (IBS-3001 and IBS-3002) conducted in more than
2,400 patients with IBS-D (13). These unique features distin-
guish eluxadoline from peripherally acting m-OR agonists such
as loperamide (14). The primary endpoint of the two phase 3
trials of eluxadoline was defined by the simultaneous im-
provement in the daily worst abdominal pain (WAP) score by
$30% compared with baseline weekly average and a reduction
in the Bristol Stool Scale (BSS) to ,5 on at least 50% of days
within a 12-week treatment period (FDA endpoint) and a 26-
week treatment period (EuropeanMedicines Agency endpoint).
The 2 studies demonstrated that eluxadoline 100 mg twice daily
had significantly greater composite responder rates as compared
with placebo.
Patient history of prior loperamide use was collected in both
phase 3 studies, and post-hoc analyses on the efficacy of elux-
adoline in patients previously treated with loperamide were
conducted (15). In total, 36% of all 2,400 patients with IBS-D in
these studies reported prior loperamide use, among whom 62%
self-reported inadequate symptom control. In the sub-
population of those not achieving adequate symptom control
with prior loperamide use, a significantly greater proportion
were composite responders following treatment with eluxado-
line as compared to placebo (15). However, this subgroup
analysis depended on patient recollection with varied durations
of prior loperamide use. Therefore, the present study was con-
ducted to further evaluate the efficacy, safety, and tolerability of
eluxadoline 100 mg twice daily in patients who reported in-
adequate IBS-D symptom control with loperamide in the pre-
ceding 12 months. It was anticipated that the findings from this
study would further our understanding on the utility of elux-
adoline among patients with IBS-D self-reported as having ex-
perienced inadequate symptom relief with loperamide.
METHODS
Study design
This was a double-blinded, randomized, placebo-controlled,
prospective, multicenter, multinational phase 4 study in adult
patients with IBS-D (trial registration NCT02959983). The study
comprised a 1-week screening period in which patients were
assessed for eligibility, followed by a 3-week pretreatment period
during which patients completed electronic patient-reported
outcome (ePRO) diaries to record daily information regarding
their IBS-D symptoms and loperamide rescue medication use.
Following the pretreatment period, eligible patients who met the
study entry criteria related to ePRO diary compliance, stool
consistency (assessed by BSS), average WAP, and use of loper-
amide rescue medication were randomized through a central
randomization system to receive eluxadoline 100 mg or placebo
twice daily for 12 weeks. During the treatment period, patients
returned to the clinic for visits at weeks 4, 8, and 12 (end-of-
treatment visit), and for a post-treatment follow-up study visit at
week 14. The total study duration was up to 18 weeks, with 7 site
visits for each patient. The study design is presented in Supple-
mentary Figure 1 (see Supplementary Digital Content 1, http://
links.lww.com/AJG/B246).
Participants
Eligible patients were 18–80 years of age, with a diagnosis of
IBS-D per Rome III criteria (defined as loose [mushy] or watery
stools $25% and hard or lumpy stools #25% of bowel move-
ments), an average WAP score of .3.0 (on a scale from 0 [no
pain] to 10 [worst imaginable pain]) in the preceding 24 hours,
an average BSS score of$5.5 (on a scale of 1 [hard lumpy stool]
to 7 [entirely liquid stool]), and a BSS score of $5 in $5 days
during the week before randomization. Prospective patients
who met the above diagnostic criteria were prescreened based
on loperamide use in the preceding 12months and self-reported
overall inadequate IBS symptom control with loperamide for
study inclusion. A follow-up questionnaire was administered,
which queried the patterns of medication usage (i.e., frequency,
duration, reason for stopping, and degree of satisfaction with
individual symptom relief including diarrhea, abdominal pain,
and improvement in bowel movement) among patients who
indicated that they managed their IBS-D using loperamide,
antidiarrheals other than loperamide, antidepressants, and
anticholinergics/antispasmodics. Patients were not allowed to use
loperamide within 14 days before randomization. Patients were also
required to complete the ePRO diary on at least 5 of the 7 days
during the week before randomization and at least 10 of the 14 days
during the 2-week pretreatment period before randomization. Key
exclusion criteria were patients with IBS with constipation, IBS with
mixed, or IBS with unsubtyped, history of inflammatory or
immune-mediated GI disorders, diverticulitis, pancreatitis, known
or suspected biliary duct obstruction, or sphincter of Oddi disease.
Patientswithout a gallbladderwere excluded in linewith theupdated
US label (12). Patients with current or expected use of any narcotic
or opioid-containing agents (e.g., antidiarrheal medications [except
loperamide rescue medication after randomization] or opioid
analgesics), or those with a history of alcohol abuse, alcohol addic-
tion, or consumption of .3 alcoholic beverages per day were also
excluded. Full eligibility criteria are included in the study protocol
(see Supplementary Digital Content 2, http://links.lww.com/AJG/
B265). The study protocol was approved and finalized before the
first patient was screened, and written informed consent was
obtained from all participants before initiation of any study-related
activities.
Study outcomes and assessments
During the double-blind 12-week treatment period, patients
recorded daily IBS-D symptoms including stool consistency
(assessed through BSS),WAP, abdominal discomfort, abdominal
bloating, bowel movement frequency, number of episodes of
urgency in a day, number of episodes of fecal incontinence, and
loperamide rescue medication use, through the ePRO diary.
The primary efficacy endpoint was the proportion of composite
responders, defined as patients who met the daily composite
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal ofGASTROENTEROLOGY
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Eluxadoline for IBS-D—RELIEF Study 1503
response criteria (daily pain response:WAP score improvement by
$40% in the preceding 24 hours and daily stool consistency re-
sponse: BSS score,5 [or absence of bowelmovement accompanied
by $40% WAP improvement compared to baseline]) for at least
50% of treatment days and had$60 days of diary entries over the
12-week treatment period. Patients with,60 days of diary entries
were considered nonresponders for the primary efficacy endpoint.
The 3 main secondary efficacy endpoints were defined as fol-
lows: (i) proportion of stool consistency responders (i.e., patients
who met the daily stool consistency for$50% of days with diary
entries over a certain time period, defined for the full 12-week
treatment period [$60 days of diary entries for the full 12 weeks]
and each 4-week interval [.20 days of diary entries for each
4-week interval]); (ii) proportion of pain responders (i.e., patients
who met the daily pain response criteria for $50% of days with
diary entries over a certain time period, defined for the full
12-week treatment period [$60 days of diary entries for the full
12 weeks] and each 4-week interval [.20 days of diary entries for
each 4-week interval]); (iii) proportion of monthly composite
responders (i.e., patients who met the daily composite response
criteria for .50% of days with diary entry for $20 days during
each 4-week interval [weeks 1–4, 5–8, and 9–12]). Patients with
,60 days of diary entry for the 12-week treatment period or,20
days of diary entries for the 4-week intervals were considered
nonresponders for the secondary efficacy endpoints.
Composite responder data were further analyzed by weekly
responders for each week up to week 12 with responders defined
in 2 ways. For definition #1, weekly composite responders were
defined as daily composite responders on $4 days for a week
(daily composite responder: $40% WAP improvement and ,5
BSS score [or absence of bowelmovement accompanied by$40%
WAP improvement compared to baseline]). For definition #2,
weekly composite responders were defined as patients with
weekly average WAP improvement of$40% from average WAP
of the baseline week and with$50% reduction in the days of BSS
score 6/7 for a study week compared with days of BSS score 6/7
during the baseline week. An analysis was also performed using
$6-week responders, wherein patients were required to meet the
2 weekly composite responder definitions defined above for at
least 6 weeks over the 12-week treatment period. Safety and tol-
erability assessed the incidence of treatment-emergent adverse
events (TEAEs). Additional endpoints are described in the study
protocol and statistical analysis plan included in the Supplemen-
taryMaterials (see Study Protocol, Supplementary Digital Content
2, http://links.lww.com/AJG/B265 and Statistical Analysis, Sup-
plementary Digital Content 3, http://links.lww.com/AJG/B266).
Statistical analyses
The trial was designed with 90% power to detect the difference
of the primary efficacy endpoint response for eluxadoline vs
placebo using a 2-sided x2 test at a significance level of 0.05.
Similar to the primary endpoint, the secondary efficacy endpoints
were analyzed using the number and percentage of the corre-
sponding responders with P-values from x2 test. No adjustment
for the multiplicity of endpoints was performed.
Diary compliance was summarized by compliance categories
(,60 vs .60 days) during the full 12-week treatment period
(;84 days) or ,20 vs .20 days for the 4-week intervals, each
corresponding to at least 70% compliance. For partial diary
entries, compliance was affirmative if either WAP score and BSS
score orWAP score and bowel movement frequency of zero were
completed. For patients who met the criteria of the minimum of
4 days of diary entry,missing diary entries were imputed using the
last observation carried forward method, the percent reduction
calculation used the imputed data. Safety data were summarized
using descriptive statistics. Adverse events were coded using the
Medical Dictionary for Regulatory Activities (MedDRA, v20.0).
Evaluation of efficacy and patient demographics was based on
the intent-to-treat population, which included all randomized
patients. For the intent-to-treat population, patients were ana-
lyzed according to their randomization assignment, regardless of
the actual treatment received. Evaluation of safety endpoints was
conducted using the safety population, which included all en-
rolled patients who received at least one dose of study drug.
For the safety population, patients were grouped and analyzed
according to the treatment they actually received. Additional
details related to statistical analysis are described in the study
protocol and statistical analysis plan included in the Supple-
mentary Materials (see Study Protocol, Supplementary Digital
Content 2, http://links.lww.com/AJG/B265 and Statistical Anal-
ysis, Supplementary Digital Content 3, http://links.lww.com/
AJG/B266).
Data availability
Data reported in this manuscript are available within the article
and its supplementarymaterials. Additional data from the RELIEF
study may be requested at http://www.allerganclinicaltrials.com/
PatientDataRequest.htm.
RESULTS
Patient disposition
The study was conducted from November 2016 to January 2018
in 82 study sites across the United States and Canada. Of the 660
screened for eligibility, 346 patients were randomized to either
placebo (n 5 174) or eluxadoline (n 5 172), and 295 (85.3%)
completed the trial (see Figure 2, Supplementary Digital Content 1,
http://links.lww.com/AJG/B246). Baseline characteristics among the
patients were similar between the placebo and eluxadoline groups.
Themean age was 44 years, 70%were women, and themedian time
since IBS-D diagnosis was 6 years. Overall, baseline IBS-D symp-
toms, including WAP, stool consistency, and patterns of bowel
movements, were also similar between the 2 groups (Table 1).
IBS-D treatment before randomization
Previous treatment for IBS-Dwas balanced between the 2 groups.
Use of antidiarrheal medications other than loperamide was
reported by 27 (15.5%) patients in the placebo group and 23
(13.4%) in the eluxadoline group (see Table 1, Supplementary
Digital Content 1, http://links.lww.com/AJG/B246). In addition,
patients also reportedmanaging their IBS-Dusing antidepressants,
anticholinergics/antispasmodics, and in fact, .60% of patients
tried at least one additional method, including lifestyle changes.
Formost patients (approximately 85%), loperamide was taken on
an as-needed basis, while approximately 11% reported daily
loperamide use (Table 2). Duration of loperamide use varied
among the patients, with 80 (46.5%) in the placebo group and
67 (39.4%) in the eluxadoline group having taken loperamide
for longer than 1 year. At randomization, 40 (23.3%) patients in
placebo as compared to 55 (32.4%) patients in the eluxadoline
group reported continued loperamide use, whereas .40% of
patients in each group reported that they had stopped taking
loperamide due to lack of improvement in their abdominal and
The American Journal of GASTROENTEROLOGY VOLUME 114 | SEPTEMBER 2019 www.amjgastro.com
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Brenner et al.1504
bowel symptoms. Although all patients self-reported overall in-
adequate symptom relief with prior loperamide use in line with
protocol requirement,;55% and;42% of patients in each treat-
ment group indicated varying degrees of satisfaction (ranging
from “a little satisfied” to “very satisfied”) with individual symptom
relief of diarrheal and abdominal pain with loperamide, re-
spectively. Conversely,;45% and;58% were “not at all satisfied”
with the degree of individual diarrheal and abdominal pain relief,
respectively, from prior loperamide use. Similarly, ;55% of
patients in each group reported varied satisfaction with decreased
urgency and improvement in bowel movement with prior loper-
amide use, whereas;45% reported lack of satisfaction. Except for
the rates of continued loperamideuse, patterns of loperamideusage
in the 12months preceding randomization were balanced between
the 2 groups (Table 2).
Primary endpoint
A statistically significantly greater proportion of eluxadoline-
treated patients achieved the primary composite responder
endpoint compared with patients treated with placebo (elux-
adoline: 22.7% [39/172], placebo: 10.3% [18/174]; P 5 0.002)
(Figure 1a). Analysis of the monthly composite endpoint re-
sponder population showed that a greater proportion of patients
treated with eluxadoline met the composite responder endpoint
during each 4-week interval compared to placebo-treated patients
(weeks 1–4: 14.0% vs 6.9%, P5 0.03; weeks 5–8: 26.7% vs 14.9%,
P 5 0.006; weeks 9–12: 30.8% vs 16.7%, P 5 0.002) (Figure 1a).
Separation of response in the daily composite responders was
observed within the initial 14 days of treatment that favored
eluxadoline and persisted throughout the study (Figure 1c).
A post-hoc analysis of daily composite endpoint responders
was performed based on the primary composite endpoint criteria
previously used in the phase 3 studies and consistent with FDA
guidance for the design and completion of IBS-D trials (daily
$30% improvement in WAP and daily stool consistency re-
sponse [BSS score ,5 or the absence of a bowel movement if
accompanied by $30% improvement in WAP]) (16). A signifi-
cantly greater proportion of patients treated with eluxadolinemet
this alternate composite responder endpoint during each of the
4-week intervals and the overall 12-week period as compared to
patients treated with placebo (weeks 1–12: 26.2% vs 13.8%, P 5
0.004; weeks 1–4: 19.2% vs 8.6%, P5 0.005; weeks 5–8: 29.7% vs
18.4%, P 5 0.013; weeks 9–12: 31.4% vs 20.1%, P 5 0.016)
(Figure 1b).
Key secondary efficacy outcomes
A prespecified analysis of composite responder data was per-
formed for weekly responders for each week up to week 12 with
responders defined in 2 ways (see METHODS section for the
definitions). During the study, a greater proportion of patients
treated with eluxadoline met the criteria for weekly composite
responders by both definitions as compared to the placebo group
at weeks 4, 5, 6, 7, 9, 11, and 12 (see Figure 3, Supplementary
Digital Content 1, http://links.lww.com/AJG/B246). Further-
more, as compared to the placebo group, treatment with elux-
adoline resulted in a significantly higher proportion of$6-week
composite responders for the analyzed weeks 1–6 (see Figure 4,
Supplementary Digital Content 1, http://links.lww.com/AJG/B246)
and weeks 1–12 (Figure 2) periods during the 12-week treatment
period for both responder definitions.
A significantly greater proportion of patients treated with
eluxadoline met the abdominal pain response endpoint over the
12-week period as compared with placebo (43.6% [75/172] vs
31.0% [54/174]; P 5 0.02) (Figure 3a). During each 4-week in-
terval, treatment with eluxadoline resulted in improvements in
WAP response over placebo (weeks 1–4: 30.2% vs 25.9%, P 5
0.38; weeks 5–8: 45.9% vs 31.6%, P5 0.005; weeks 9–12: 44.8% vs
35.1%, P 5 0.06). Abdominal pain responder data were further
analyzed for patients who met daily 30% and 50% pain response
criteria for $50% of days with diary entries over either the full
12-week treatment period or the three 4-week intervals. Treat-
ment with eluxadoline resulted in a greater proportion of pain
responders with both 30% and 50% improvement in WAP as
compared with placebo during the overall 12-week treatment
period and over the 4-week intervals (Figures 3b,c). In addition,
a significantly greater proportion of patients treated with elux-
adoline over the 12-week period were stool consistency
Table 1. Patient baseline demographics and characteristics
Placebo
(n5 174)
Eluxadoline
(n5 172)
Age, mean yr (SD) 43.9 (14.2) 43.8 (13.9)
Women, n (%) 119 (68.4) 124 (72.1)
White, n (%) 141 (81.0) 144 (83.7)
Not Hispanic or Latino, n (%) 133 (76.4) 139 (80.8)
Weight, mean kg (SD) 86.3 (24.7) 84.1 (23.7)
Height, mean cm (SD) 168.6 (9.6) 167.7 (10.6)
BMI, mean kg/m2 (SD) 30.4 (8.3) 29.9 (8.0)
Duration of IBS-D, median yr
(Q1, Q3)
7.0 (3.0, 14.7) 6.0 (2.6, 14.0)
Weekly average of daily worst
abdominal pain, mean (SD)
6.0 (1.6) 6.3 (1.5)
Stool consistency, BSS, mean (SD) 6.2 (0.4) 6.2 (0.4)
Weekly average of daily abdominal
discomfort, mean (SD)
6.2 (1.6) 6.4 (1.5)
Weekly average of daily abdominal
bloating, mean (SD)
6.2 (1.9) 6.5 (1.6)
Weekly average of daily number of
bowel movement frequency,
mean (SD)
4.2 (2.3) 4.0 (1.8)
Weekly average of daily number of
urgency episodes, mean (SD)
2.9 (2.4) 2.7 (1.8)
Weekly average of daily number of
bowel incontinence episodes, mean
(SD)
1.1 (2.0) 1.2 (2.0)
Weekly average of incontinence-free
days, mean (SD)
5.3 (1.8) 5.2 (1.8)
Diary compliance,$60 entries within
84 days, n (%)
127 (73.4) 131 (76.6)
Diary compliance based on double-blind treatment period (84 days) using the
safety population.
P-values were not significant (P. 0.05) for each parameter; P-values for
continuous variables were based on t-test; analysis for categorical variables
were based on x2 test.
BMI, bodymass index; BSS,Bristol Stool Scale; IBS-D, irritable bowel syndrome
with diarrhea; Q1, first quartile; Q3, third quartile.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal ofGASTROENTEROLOGY
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Eluxadoline for IBS-D—RELIEF Study 1505
responders as compared with placebo (27.9% [48/172] vs 16.7%
[29/174]; P 5 0.01) (Figure 3d). During each of the 4-week
intervals, greater improvements in stool consistency response
were observed with eluxadoline as compared to placebo. Col-
lectively, these data demonstrated greater symptom improve-
ment in key secondary endpoints throughout the 12-week
treatment period with eluxadoline as compared to placebo. A
summary of key efficacy endpoints is provided in Supplemen-
tary Table 2 (see SupplementaryDigitalContent 1, http://links.lww.
com/AJG/B246).
Safety and tolerability
A total of 112 TEAEs were reported in the placebo group and 124
TEAEs in the eluxadoline group. The proportion of patients
reporting at least one TEAE was comparable with eluxadoline
(37.4% [64/171]) and placebo (35.3% [61/173]) (Table 3). Higher
rates of treatment-related TEAEs were reported in the eluxado-
line group (15.8% [27/171]) as compared to the placebo group
(5.8% [10/173]). TEAEs leading to premature treatment dis-
continuations and study discontinuations were higher in the
eluxadoline group (5.8% [10/171] and 2.9% [5/171], respectively)
compared to the placebo group (1.7% [3/173] and 0.6% [1/171],
respectively), whereas a higher rate of severe TEAEs was reported
in the placebo group (2.9% [5/173]) as compared to the elux-
adoline group (1.8% [3/171] [Table 3]). Three patients in the
placebo group (1.7%) and 1 patient in the eluxadoline group
(0.6%) experienced serious TEAEs (summarized in Table 3,
Supplementary Digital Content 1, http://links.lww.com/AJG/
B246), none of which were related to treatment.
Gastrointestinal AEs (GIAEs) were the most common
treatment-emergent events, with a higher rate reported in the
eluxadoline group (17.0% [29/171]) as compared to the placebo
Table 2. Patterns of loperamide usage in the 12 months preceding randomization
Question Response
Placebo (n 5 174) Eluxadoline (n5 172)
n (%) n (%)
Patients who took loperamide in the
preceding 12 monthsa
Yes 172 (98.9) 170 (98.8)
Frequency
“How do (or did) you use this medication?”
Daily 19 (11.0) 23 (13.5)
As needed 150 (87.2) 144 (84.7)
Other 3 (1.7) 3 (1.8)
Duration
“How long have you taken (or did you take)
this medication?”
Less than 1 week 19 (11.0) 33 (19.4)
Greater than 1 week but less than 1 month 21 (12.2) 20 (11.8)
Greater than 1 month but less than 3 months 13 (7.6) 17 (10.0)
Greater than 3 months but less than 6 months 19 (11.0) 17 (10.0)
Greater than 6 months but less than 1 year 20 (11.6) 16 (9.4)
Greater than 1 year 80 (46.5) 67 (39.4)
Reason for stopping loperamide
“If you stopped taking this medication, what
was the reason?” (more than one answer was
allowed)
Not applicable (currently taking loperamide) 40 (23.3) 55 (32.4)
It did not improve my abdominal symptoms 74 (43.0) 67 (39.4)
It did not improve my bowel symptoms 78 (45.3) 77 (45.3)
I experienced side effect 8 (4.7) 8 (4.7)
It costs too much 5 (2.9) 5 (2.9)
Other 5 (2.9) 7 (4.1)
Satisfaction with diarrheal relief
“Overall, how satisfied are (or were) you with
the medication’s ability to relieve your
diarrhea?”
Not at all satisfied 75 (43.6) 78 (45.9)
A little satisfied 61 (35.5) 64 (37.6)
Moderately satisfied 29 (16.9) 22 (12.9)
Quite satisfied 5 (2.9) 6 (3.5)
Very satisfied 2 (1.2) 0
Satisfaction with abdominal pain relief
“Overall, how satisfied are (or were) you with
the medication’s ability to relieve your
abdominal pain?”
Not at all satisfied 101 (58.7) 99 (58.2)
A little satisfied 48 (27.9) 54 (31.8)
Moderately satisfied 20 (11.6) 14 (8.2)
Quite satisfied 1 (0.6) 3 (1.8)
Very satisfied 2 (1.2) 0
Satisfaction with improvements in bowel
movements
“Overall, how satisfied are (or were) you with
the medication’s ability to decrease the
number of times you experienced urgency in
relation to your bowel movements (sudden,
almost irresistible need to have a bowel
movement)?”
Not at all satisfied 80 (46.5) 75 (44.1)
A little satisfied 55 (32.0) 62 (36.5)
Moderately satisfied 30 (17.4) 27 (15.9)
Quite satisfied 5 (2.9) 5 (2.9)
Very satisfied 2 (1.2) 1 (0.6)
aA database entry error resulted in the erroneous notation that 2 patients in each group did not take loperamide before study enrollment. The affected sites were queried,
and study questionnaires confirmed that all 4 patients took loperamide in the preceding 12 months as required by the inclusion criteria; however, the error was left as
recorded since correction of this discrepancy would have required retroactive correction of source data.
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group (6.4% [11/173]). Most GIAEs were mild-to-moderate in
intensity, with 3 severe events reported in the eluxadoline group
(Table 3). Of these, 1 event (pancreatic mass) was a serious AE,
which was unrelated to treatment, from which the patient re-
covered and the drug was withdrawn. Of all TEAEs, nausea was
the most common event at 5.8% (10/171) in the eluxadoline
group as compared to the 2.9% (5/173) reported in the placebo
group. A summary of TEAEs $2% in any group is provided by
preferred term inTable 3.No episodes of pancreatitis or sphincter
of Oddi spasm were reported in the study.
DISCUSSION
Loperamide, a m-OR agonist that reduces the frequency of
bowel movements and improves stool consistency, is
Figure1.Analyses of composite responders. (a) Composite endpoint of daily responders (i.e., patients whomeet daily composite response criteria on
$50% of days, defined as$40% improvement in WAP compared with baseline and BSS score,5 [or the absence of a bowel movement if accompanied
by$40% improvement in WAP]). Monthly composite responders are patients who met the daily composite response criteria on $50% of days and had
a minimum of 20 days of diary entries for each 4-week interval. (b) A post-hoc analysis of composite responders defined at$30% improvement in WAP
compared with baseline pain and daily stool consistency response. For both analyses, any patient with fewer than 20 days of diary entries for the 4-week
interval was considered as a nonresponder. (c) Daily composite responders ($40% WAP improvement and BSS score,5) over time. BSS, Bristol Stool
Scale; WAP, worst abdominal pain. P-values are based on x2 test.
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frequently used as a first-line agent for IBS-D. However,
studies have revealed that loperamide is ineffective in treating
the abdominal symptoms of IBS (1,7–11). Use of IBS treat-
ments with limited efficacy may result in additional medical
visits, investigations, and adoption of other therapeutic
approaches, including agents with minimal evidence of benefit
(17,18). Such “treatment-failure” patients are challenging to
treat, as diminishing returns often are experienced with ad-
ditional therapeutic interventions; moreover, these patients
frequently suffer from higher psychological and nonpain
comorbidities, further complicating their treatment (19). In
the present study, most patients reported use of other anti-
diarrheals, antidepressants, anticholinergics, and lifestyle
modifications before enrollment, indicating a clear need for
safe and effective agents that achieve sustained global relief of
IBS-D earlier and more efficaciously.
In this multicenter, randomized, controlled phase 4 study
of eluxadoline vs placebo in patients with IBS-D who reported
inadequate symptom control with loperamide in the 12
months preceding the study, we found that a significantly
greater proportion of patients receiving eluxadoline achieved
daily improvement in abdominal pain ($40%) and stool
consistency (,5 BSS score, or absence of bowel movement)
for at least 50% of treatment days. These improvements were
observed within the initial 4 weeks of treatment and sustained
until the end of the study. Similarly, the monthly composite
responder endpoints were met by a higher proportion of
eluxadoline-treated patients than those who received placebo.
A higher percentage of patients receiving eluxadoline also
achieved the secondary endpoints of improvements in stool
consistency and abdominal pain compared to placebo.
In the two phase 3 studies (IBS-3001 [52-week treatment]
and IBS-3002 [26-week treatment]) evaluating the safety
and efficacy of eluxadoline, the primary composite endpoint
was defined as a concurrent $30% improvement in daily
abdominal pain score compared with baseline and a BSS score
,5 on at least 50% of days within a 12-week treatment period
(FDA endpoint) and a 26-week treatment period (European
Medicines Agency endpoint) (13). In both studies, eluxado-
line demonstrated significantly greater composite responder
rates compared to placebo over the respective treatment
periods. Subsequently, a retrospective analysis of these phase
3 data was performed to evaluate the efficacy of eluxadoline in
patients who had been previously treated with loperamide
(15). Over one-third of patients (873/2,428) in the phase
3 studies reported prior loperamide use, among whom nearly
60% (538/873) self-reported inadequate loperamide symp-
tom control; in this subpopulation, a significantly greater
proportion were composite responders following treatment
with 100 mg of eluxadoline compared to placebo over 12
weeks (15). Similar to the retrospective analysis of phase
3 trial data, a significantly greater proportion of loperamide-
unresponsive patients in the current prospective study
met the responder criteria with eluxadoline as compared to
placebo over 12 weeks of treatment. Notably, in the current
trial, a more stringent definition was set for daily clinical
responders as a patient with IBS-D had to achieve $40%
improvement in WAP. Despite this more stringent endpoint,
the results herein are similar to those observed in the phase
3 trials.
We also performed a post-hoc analysis using the phase 3
study primary endpoint criteria ($30% WAP improvement
and a reduction to ,5 in the BSS score) and found that a sig-
nificantly higher proportion of eluxadoline-treated patients
achieved this FDA-mandated composite responder criteria
compared to placebo over 12 weeks of treatment. Moreover,
a similar treatment effect on the 12-week primary endpoint
was also achieved for the phase 3 subpopulation who reported
lack of adequate symptom control with prior loperamide
use at 12 and 26 weeks (15). Therefore, the reproducibility of
the phase 3 analysis in the current study further
substantiates the positive treatment effect of eluxadoline on
the composite endpoint and in the context of previous
loperamide failure.
IBS and its range of symptoms are often difficult to treat;
however, these collective data show favorable results in the
patient population who have failed loperamide, a treatment
often used as standard of care. The positive outcomes of this
study in a real-world setting suggest that eluxadoline may be
an option for those who have previously used loperamide.
Abdominal pain, a major clinical feature of IBS, is often the
most challenging to treat and is closely linked to disease se-
verity (20–22). Analysis of a $40% improvement in abdom-
inal pain threshold over 12 weeks demonstrated a significantly
higher responder rate in the eluxadoline group compared to
placebo. Significant differences were maintained when the
data were imputed using$30% abdominal pain improvement
criteria as was used in the phase 3 studies, as well as for the
Figure 2. Weekly composite responder during the 12-week treatment
period, and for at least 6 weeks out of 12 weeks from weeks 1–12 by
2 definitions. Definition #1 5 weekly composite responder is defined
as daily composite responder on$4 days for a week. Daily composite
responder5WAP improvement by$40% compared with baseline and
BSS score ,5 (or the absence of bowel movement if accompanied by
$40% improvement in WAP) compared to baseline. Definition #2 5
weekly composite responder is defined as patients with weekly average
WAP improvement of $40% from average WAP of the baseline week
and with $50% reduction in the days of BSS score 6/7 for a week com-
paring with days of BSS score 6/7 during the baseline week. BSS, Bristol
Stool Scale; WAP, worst abdominal pain. P-values are based on x2 test.
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stricter $50% abdominal pain improvement pain response.
These data are generally in line with the phase 3 studies, which
showed that the $30% abdominal pain response component
showed an improvement, although not statistically signifi-
cant, for eluxadoline over placebo in the overall population.
The experience of abdominal pain in IBS is complex and is
influenced by a multitude of patient factors, including psy-
chological comorbidity, previous abuse experiences, and non-
GI pain comorbidities. Additionally, environmental factors
including diet and stress can further modulate these symptom
experiences (23). Data from the current study showed sig-
nificant improvements in abdominal pain across a wide range
of subjective pain endpoints. Stool consistency response was
also similar to the primary composite rate over the 12-week
treatment period, and collectively, our data suggest that the
overall response of the composite endpoint was driven by
Figure3.Analysis of pain and stool consistency responders. (a)Monthly pain responders (i.e., patientswhomet the daily pain response criteria for$50%of
days with diary entries over a certain time period, defined for the full 12-week treatment period [$60 days of diary entries for the full 12 weeks] and each
4-week interval [.20 days of diary entries for each 4-week interval] as$40% improvement in WAP compared with baseline). Analysis of responders who
met the daily (b) 30% and (c) 50% improvement in WAP. (d) Analysis of monthly stool consistency responders (i.e., patients who met the daily stool
consistency for$50% of days with diary entries over a certain time period, defined for the full 12-week treatment period [$60 days of diary entries for
the full 12 weeks] and each 4-week interval [.20 days of diary entries for each 4-week interval]) compared with baseline. WAP, worst abdominal pain.
P-values are based on x2 test.
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significantly higher response in stool consistency in the early-
to-mid timepoints and by significant improvements in ab-
dominal pain in the mid-to-later timepoints of the trial. The
mechanistic basis for these observed differences with the
mixed m-OR agonist eluxadoline has not been fully elucidated
but are presumed related to the combined k-opioid receptor
agonist and d-OR antagonist characteristics unique to this
agent.
The most common TEAEs in the study were GI, indicative
of the local (GI) pharmacological effects of eluxadoline.
GIAEs, including nausea, constipation, abdominal pain, and
vomiting, were reported more frequently in the eluxadoline
than the placebo group. Most GIAEs in the present study were
mild or moderate in intensity. Three severe events were
reported in the eluxadoline group, including vomiting, ab-
dominal distension, and pancreatic mass, which were adju-
dicated as unrelated to eluxadoline. The single serious AE
reported in the eluxadoline cohort was a pancreatic mass in
a patient with a history of chronic alcohol consumption. This
was assessed by investigators as unrelated to treatment, but
treatment was withdrawn, and the pancreatic mass resolved
without sequelae. It is noteworthy that no cases of pancreatitis
or sphincter of Oddi spasm were reported in the present
study.
In summary, results of the current study demonstrate
positive treatment benefits for eluxadoline over placebo in
patients with IBS-D reporting inadequate symptom relief
from loperamide, based on improvements in both abdominal
pain and stool consistency, the cardinal symptoms of IBS.
Moreover, the safety profile of eluxadoline was comparable to
placebo, with no new safety concerns identified. We conclude
that this study prospectively validates previous findings re-
vealing eluxadoline to be a safe, effective IBS-D treatment in
patients reporting inadequate symptom relief with prior
loperamide use.
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Table 3. Summary of treatment-emergent adverse events
Placebo
(n5 173)
Eluxadoline
(n5 171)
n (%) n (%)
Total number of TEAEs 112 124
Patients with at least one TEAE 61 (35.3) 64 (37.4)
Treatment-related TEAE 10 (5.8) 27 (15.8)
Treatment discontinuations due to a TEAE 3 (1.7) 10 (5.8)
Study discontinuations due to a TEAE 1 (0.6) 5 (2.9)
Severe TEAE 5 (2.9) 3 (1.8)
Treatment-emergent serious AE 3 (1.7) 1 (0.6)
GIAEs 11 (6.4) 29 (17.0)
Severe 0 3 (1.8)
Vomiting 0 1 (0.6)
Abdominal distension 0 1 (0.6)
Pancreatic mass 0 1 (0.6)
Moderate 6 (3.5) 10 (5.8)
Mild 5 (2.9) 16 (9.4)
TEAEs$2% in any group
Nausea 5 (2.9) 10 (5.8)
Constipation 2 (1.2) 8 (4.7)
Nasopharyngitis 4 (2.3) 6 (3.5)
Influenza 4 (2.3) 5 (2.9)
Sinusitis 2 (1.2) 5 (2.9)
Headache 1 (0.6) 5 (2.9)
Upper respiratory tract infection 0 5 (2.9)
Abdominal pain 3 (1.7) 4 (2.3)
Vomiting 1 (0.6) 4 (2.3)
Blood creatinine increased 2 (1.2) 4 (2.3)
Pancreatitis episodes 0 0
Sphincter of Oddi spasm 0 0
Deaths 0 0
TEAE is defined as any AE with a start date that is on or after the start date of
study medication, or any preexisting AE worsened either in intensity or
frequency after taking the first dose of the study medication. Serious AEs
were classified based on seriousness (i.e., if it resulted in death, was life-
threatening, resulted in inpatient hospitalization or prolongation of
existing hospitalization, was persistent or caused significant disability/
incapacity, or resulted in a congenital anomaly/birth defect). Severity of
AEs was based on intensity (i.e., mild, moderate, severe, or not applicable
if it cannot be graded) and how it impacted usual activity.
AE, adverse event; GIAE, gastrointestinal AE; TEAE, treatment-emergent
adverse event.
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Study Highlights
WHAT IS KNOWN
3 Eluxadoline is an FDA-approved therapy for the treatment of
IBS-D.
3 In post-hoc analyses of phase 3 clinical trials, patients failing
to experience improvements in their IBS symptoms from
loperamide appeared to derive symptomatic benefits from
eluxadoline.
WHAT IS NEW HERE
3 Eluxadoline improves IBS-D symptoms in individuals
subjectively reporting inadequate responses to loperamide.
3 Eluxadoline improves both pain and bowel functions in
individuals reporting inadequate responses to loperamide.
3 In a population of individuals with IBS-D with an intact
gallbladder, no events of sphincter of Oddi spasm or
pancreatitis occurred while taking eluxadoline.
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